World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
88
Citations
39118
World Ranking
12952
National Ranking
495

Jan J. Cornelissen publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Jan J. Cornelissen sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 573 publications — 68th percentile

68% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Jan J. Cornelissen D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Jan J. Cornelissen sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 88 D-Index — 36th percentile

36% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Jan J. Cornelissen is affiliated with Erasmus University Rotterdam in the Netherlands. Their research primarily focuses on Medicine with a significant emphasis on Hematology. Their work spans several interconnected subfields including Public Health, Environmental and Occupational Health, Genetics, Oncology, and Immunology.

Their scientific contributions cover a range of topics, including:

  • Hematopoietic Stem Cell Transplantation
  • Acute Myeloid Leukemia Research
  • Acute Lymphoblastic Leukemia research
  • Chronic Myeloid Leukemia Treatments
  • Chronic Lymphocytic Leukemia Research
  • Immune Cell Function and Interaction
  • Myeloproliferative Neoplasms: Diagnosis and Treatment

Jan J. Cornelissen has published extensively in several journals. The most frequent publication venues include:

  • Blood
  • Bone Marrow Transplantation
  • HemaSphere
  • Haematologica
  • Blood Advances

Among recent notable papers affiliated with or related to their research focus are:

  • Duration and key determinants of infectious virus shedding in hospitalized patients with coronavirus disease-2019 (COVID-19), 2021, Nature Communications
  • Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation, 2020, The Lancet Haematology
  • Shedding of infectious virus in hospitalized patients with coronavirus disease-2019 (COVID-19): duration and key determinants, 2020, bioRxiv (Cold Spring Harbor Laboratory)
  • Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome, 2022, Blood
  • Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients, 2020, Bone Marrow Transplantation

Collaboration appears to be a prominent aspect of their research as evidenced by frequent co-authors, including:

  • Mohamad Mohty
  • Myriam Labopin
  • Arnon Nagler
  • Didier Blaise
  • Ibrahim Yakoub-Agha

Jan J. Cornelissen's work reflects a strong concentration on hematological malignancies and stem cell transplantation, integrating clinical and translational aspects. Their multidisciplinary approach spans molecular characterization, clinical management, and public health implications within the broader field of medicine.

Best Publications

  • Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

    Stephen G. O'Brien;François Guilhot;Richard A. Larson;Insa Gathmann

  • Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

    Brian J. Druker;François Guilhot;Stephen G. O'brien;Insa Gathmann

  • Human fetal lymphoid tissue–inducer cells are interleukin 17–producing precursors to RORC + CD127 + natural killer–like cells

    Tom Cupedo;Natasha K Crellin;Natalie Papazian;Elwin J Rombouts

  • Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation

    Richard E. Champlin;Norbert Schmitz;Mary M. Horowitz;Bernard Chapuis

  • Duration and key determinants of infectious virus shedding in hospitalized patients with coronavirus disease-2019 (COVID-19).

    Jeroen J. A. van Kampen;David A. M. C. van de Vijver;Pieter L. A. Fraaij;Bart L. Haagmans

  • Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom?

    Jan J. Cornelissen;Wim L. J. van Putten;Leo F. Verdonck;Matthias Theobald

  • Prevalence and Clinical Symptoms of Human Metapneumovirus Infection in Hospitalized Patients

    Bernadette G. van den Hoogen;Gerard J. J. van Doornum;John C. Fockens;Jan J. Cornelissen

  • Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies: an individual patient data meta-analysis of nine randomized trials

    Mahmoud al-Jurf;Mahmoud al-Jurf;Francisco Aranha;Francisco Aranha;Claudio Annasetti;Jane F. Apperley;Jane F. Apperley

  • Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation

    Olaf Penack;Monia Marchetti;Tapani Ruutu;Mahmoud Aljurf

  • Acute myeloid leukaemia.

    Asim Khwaja;Magnus Bjorkholm;Rosemary E Gale;Ross L Levine

  • Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell--depleted SCT

    Joost W. J. van Esser;Bronno van der Holt;Ellen Meijer;Hubert G. M. Niesters

  • Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe 2009.

    P. Ljungman;M. Bregni;M. Brune;J. Cornelissen

  • Increased transplant-related morbidity and mortality in CMV-seropositive patients despite highly effective prevention of CMV disease after allogeneic T-cell-depleted stem cell transplantation.

    A. E. C. Broers;R. van der Holt;J. W. J. van Esser;J. W. Gratama

  • Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation.

    Joost W. J. van Esser;Hubert G. M. Niesters;Bronno van der Holt;Ellen Meijer

  • The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach

    Jan J. Cornelissen;Alois Gratwohl;Richard F. Schlenk;Jorge Sierra

  • Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections

    Acap Leenders;Simon Daenen;Rlh Jansen;Wcj Hop

  • Tetramer-based quantification of cytomegalovirus (CMV)-specific CD8+ T lymphocytes in T-cell-depleted stem cell grafts and after transplantation may identify patients at risk for progressive CMV infection

    Jan W. Gratama;Joost W. J. van Esser;Cor H. J. Lamers;Claire Tournay

  • Reduced-Intensity Conditioning Compared With Conventional Allogeneic Stem-Cell Transplantation in Relapsed or Refractory Hodgkin's Lymphoma: An Analysis From the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation

    Anna Sureda;Stephen Robinson;Carmen Canals;Angelo M. Carella

  • Development of a Real-Time Quantitative Assay for Detection of Epstein-Barr Virus

    H. G. M. Niesters;J. van Esser;E. Fries;K. C. Wolthers

  • Impact of FLT3 Internal Tandem Duplication on the Outcome of Related and Unrelated Hematopoietic Transplantation for Adult Acute Myeloid Leukemia in First Remission: A Retrospective Analysis

    Salut Brunet;Myriam Labopin;Jordi Esteve;Jan Cornelissen

Frequent Co-Authors

Arnon Nagler
Arnon Nagler Sheba Medical Center
Myriam Labopin
Myriam Labopin Université Paris Cité
Gérard Socié
Gérard Socié Université Paris Cité
Bob Löwenberg
Bob Löwenberg Erasmus MC
Ibrahim Yakoub-Agha
Ibrahim Yakoub-Agha University of Lille
Jakob Passweg
Jakob Passweg University Hospital of Basel
Nicolaus Kröger
Nicolaus Kröger Universität Hamburg
Dietger Niederwieser
Dietger Niederwieser Leipzig University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring medicine in the USA opens doors to a range of specialized healthcare careers beyond becoming a physician. Many students consider alternative or complementary pathways, such as healthcare administration, nursing leadership, pharmacy practice, and health information management.

For those interested in the business and organizational side of healthcare, pursuing one of the cheapest mha programs online is an excellent option. These programs prepare graduates for roles leading hospitals and healthcare systems.

Nurses looking to advance their clinical expertise may explore the best dnp programs online. Earning a Doctor of Nursing Practice (DNP) can open opportunities in advanced practice, administration, and teaching.

For those drawn to medication management and patient care, there are increasingly flexible online pharm d programs offering paths to become a licensed pharmacist.

Technology-driven roles are also growing. Earning a degree through rhia certification programs online can pave the way to becoming a Registered Health Information Administrator (RHIA), an essential role in medical data and compliance.

With a wide range of accredited and affordable online degrees, future healthcare professionals can find the right fit for their career goals and schedules.

Best Scientists Citing Jan J. Cornelissen

Trending Scientists

Recently Published Articles